SECTIONS
SUBSCRIBE
Managed Care

Search form

  • News
  • Politics & policy
  • Drug management
  • Payers
  • Providers
  • Current Issue
  • More
    • Past issues
    • Value-Based Care
    • Profiles
    • Conversations
    • Tomorrow's Medicine
    • Original research
    • Pharm D Corner
    • Viewpoints
    • Legislation & regulation
    • Contact Us

Most Popular

Why Medicaid Managed Care Is Looking Outside the Traditional Coverage Box

Social factors, like access to healthy food, stable housing, a steady income, and reliable transportation, may have more to do with a sick person getting well than anything that a health plan, doctor, or hospital can do. That’s been well documented by numerous studies and the likes of the World Health…
Read more

#Metoo and American Health Care

As we went to press, the first of what may be up to 100 women were giving their victims statements against Larry Nassar, the former team doctor for the USA Gymnastics team. Nassar had already pleaded guilty to 10 counts of sexually assaulting young girls, and prosecutors had recommended a stiff sentence…
Read more

Value-Based Health Care Offers Answers and Questions

The sitcom created by Chris Rock, Everybody Hates Chris, which ran from 2005 until 2009, conjured laughs out of the everyday. One bit I particularly relish is when the narrator (the persona of Rock as a teenager) says that his father was like Rain Man when it came to knowing what everything costs. “That’s…
Read more

FDA Approves Xgeva for Prevention of Skeletal Events In Multiple Myeloma

The FDA has expanded the approved indications for denosumab (Xgeva, Amgen) to include the prevention of skeletal-related events in patients with bone metastases with multiple myeloma. The medication was already approved to prevent skeletal events in patients with bone metastases from solid tumors. The…
Read more

How RWE Is Becoming the Real Deal

The randomized controlled trial reigns supreme, but the FDA is working on ways to incorporate real-world evidence into its approval processes.

Read more

Ending Medicaid as We’ve Known It

The Trump administration and CMS Administrator Seema Verma are on their way to giving the 53-year-old Medicaid program a major makeover, changing it from being an entitlement program based on income to something that may more closely resemble a temporary assistance program with work, premiums, and other…
Read more

FDA Clears the First Smart Watch for Use in Neurology

The FDA has cleared the Embrace smart watch (Empatica, Inc.) for use by patients with epilepsy. Embrace uses advanced machine learning to monitor for the most dangerous kinds of seizures, known as “grand mal” or “generalized tonic-clonic” seizures, and sends an alert to summon caregivers’…
Read more

Zytiga Approved to Treat Earlier Form of Metastatic Prostate Cancer

Abiraterone acetate (Zytiga, Janssen Pharmaceutical) in combination with prednisone has received FDA approval for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (CSPC). Approval of the new indication is based on phase 3 data from the pivotal LATITUDE clinical…
Read more

ASHP Survey: IV Fluid Bag Shortage Affecting Patient Care

The shortage of small-volume parenteral solutions often supplied in intravenous fluid bags is affecting virtually all U.S. hospitals, according to results of a survey by the American Society of Health-System Pharmacists (ASHP). Nearly all of the respondents (99.1%) to the informal, nonscientific survey…
Read more

Making Work a Must-Do for Medicaid

Kentucky was the first state to take advantage of the Trump administration’s invitation for states to set work requirements for Medicaid, but others are sure to follow.

Read more

FDA Approves the First Oral Liquid for Valsartan in the U.S.

The FDA has approved valsartan oral solution (Prexxartan, Medicure), the first and only approved oral liquid dosage form of the angiotensin II receptor blocker valsartan in the United States. Previously, on October 31, 2017, Medicure announced that, through its subsidiary, Medicure International, Inc.,…
Read more

FDA OKs Single-Shot Dexycu to Replace Eye Drops After Cataract Surgery

The FDA has approved dexamethasone intraocular suspension (Dexycu, Icon Bioscience, Inc.), a long-acting treatment for inflammation associated with cataract surgery that allows patients to dispense with weeks of self-administered eye drops. Under the current standard of care for inflammation associated…
Read more

FDA Approves Once-Daily Osmolex ER for Parkinson’s Disease Treatment

The FDA has approved an amantadine extended-release tablet (Osmolex ER, Osmotica Pharmaceutical) for the treatment of Parkinson’s disease and for the treatment of drug-induced extrapyramidal reactions in adults. Extrapyramidal symptoms are known side effects of many common medications. Osmolex ER…
Read more

Questions Health Plans Must Ask Before Considering a Laboratory Benefit Management or Prior Authorization Program

These eight questions show that the use of an LBM or a PAP should be just one of the potential results of your laboratory benefit management program, not the program itself. You shouldn’t have to pay for services you already provide yourselves or add a middleman that’s not necessary.

Read more

340B Program Fails to Meet Its Promise, Study Finds

The 340B Drug Pricing Program, a 25-year-old discount plan aimed at boosting resources for hospitals treating low-income patients, has not delivered on its promise to enhance care for the needy, according to research from Harvard Medical School and the NYU School of Medicine. The federal program was…
Read more

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »
Facebook Twitter LinkedIn RSS Feed
  • Contact Us
  • Our History
  • Terms & Conditions of Use Agreement
  • Address and Subscription Changes
  • 2018 Editorial Calendar
  • 2018 Space and Material Due Dates
  • BPA Statement
  • Submitting Original Research
  • Submitting Viewpoints
  • Site Map
  • Contact Webmaster
  • P&T Community
© 2018 MediMedia, an ICON plc company. All rights reserved.